Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.64 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181611 | 0.88 | ROCK1 (0.57) | MAPK1MAPK3ROCK2ROCK1ADORA3 | |
| SCHEMBL20181599 | 0.87 | ROCK2 (0.74) | MAPK1MAPK3ROCK2ROCK1ADORA3 | |
| SCHEMBL20181640 | 0.86 | ROCK2 (0.79) | MAPK1MAPK3ROCK2ROCK1MME | |
| SCHEMBL20181594 | 0.86 | ROCK2 (0.79) | MAPK1MAPK3ROCK2ROCK1MME | |
| SCHEMBL20181593 | 0.79 | MAPT (0.58) | MAPK1ROCK2ROCK1ADORA3ADORA2A | |
| SCHEMBL20181396 | 0.76 | ROCK1 (0.78) | MAPK1MAPK3ROCK2ROCK1ADORA3 | |
| SCHEMBL20181642 | 0.76 | ROCK1 (0.78) | MAPK1MAPK3ROCK2ROCK1ADORA3 | |
| SCHEMBL13986931 | 0.75 | ALDH1A1 (0.52) | MAPK1MAPK3ROCK2ROCK1PRKG1 | |
| SCHEMBL13986933 | 0.75 | ALDH1A1 (0.52) | MAPK1MAPK3ROCK2ROCK1PRKG1 | |
| SCHEMBL13986977 | 0.75 | ALDH1A1 (0.52) | MAPK1MAPK3ROCK2ROCK1PRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-09-19 | — | — | US | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | MAPK1 33/4885MAPK3 29/4885ROCK2 76/4885 |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | MAPK1 33/4885MAPK3 29/4885ROCK2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.